Boehringer Ingelheim Convenes Educational Meetings to Empower Over 300 Regional Experts with Latest Heart Failure Advances
• Boehringer Ingelheim hosted ‘Heart Talks’and ‘MEDEX’ to discuss latest updates in heart failure management and help improve patient outcomes across India, the Middle East and Africa
Same as with humans, body weight is just one indicator among many when it comes to a pet’s health status. However, there are some diseases associated with it. Learn more here.
Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A
The pyramid®/presponse® family of vaccines provides broad coverage for BVD types 1 and 2, IBR, BRSV, PI3 and Mannheimia haemolytica with only a single dose.
Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. There is a simple test that can help everyone identify the most common symptoms of a stroke.
Empowering and Upskilling Patient Organizations in the IMETA Region
Boehringer Ingelheim held the first PULSE training programme in Dubai, bringing together over twenty representatives of patient organizations from across India, the Middle East, Turkey, and Africa.